Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

Retrovirology

Volumn 7, Issue , 2010, Pages

  Bercoff, Danielle P ^a   Triqueneaux, Perrine ^b   Lambert, Christine ^a   Oumar, Aboubacar A ^c   Ternes, Anne Marie ^a   Dao, Sounkalo ^c   Goubau, Patrick ^b   Schmit, Jean Claude ^a   Ruelle, Jean ^b  

^a Retrovirology Laboratory Luxembourg   (Luxembourg)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF BAMAKO   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; ENZYME ACTIVITY; FEMALE; GENETIC CONSERVATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC 50; IN VITRO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DNA BINDING; PROTEIN MOTIF; RESIDUE ANALYSIS; SCHOOL CHILD; SEQUENCE ALIGNMENT; STRAIN DIFFERENCE; SURFACE CHARGE; VIRUS CULTURE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CELL LINE; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; PHYLOGENY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; PYRROLIDINONES;

EID: 78650845158     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-98     Document Type: Article

References (40)

1. Roquebert B, Matheron S, Benard A, Leleu J, Tubiana R, Karmochkine M, Chene G, Damond F, Brun-Vezinet F, . Diane Descamps, and on behalf the French HIV-2 ANRS Cohort CO5 Raltegravir Genetic Resistance Patterns in HIV-2 Infected Patients Failing Raltegravir-containing Regimen. CROI; San Fransisco 2010, Diane Descamps, and on behalf the French HIV-2 ANRS Cohort CO5., http://retroconference.org/AbstractSearch/Default.aspx?Conf=19
2. Rowland-Jones SL, Whittle HC. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1?. Nat Immunol 2007, 8:329-331. 10.1038/ni0407-329, 17375091.
3. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010, 54:718-727. 10.1128/AAC.00986-09, 2812151, 19933797.
4. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004, 9:57-65.
5. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants?. AIDS Res Hum Retroviruses 2004, 20:347-348. 10.1089/088922204322996590, 15117459.
6. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005, 43:484-487. 10.1128/JCM.43.1.484-487.2005, 540186, 15635022.
7. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:4680-4686. 10.1128/AAC.48.12.4680-4686.2004, 529207, 15561844.
8. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, Campa P, Matheron S, Chene G, Brun-Vezinet F, Descamps D. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008, 52:1545-1548. 10.1128/AAC.01284-07, 2292533,2292533, 18227188.
9. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006, 57:709-713. 10.1093/jac/dkl034, 16464891.
10. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007, 51:604-610. 10.1128/AAC.00870-06, 1797771, 17116674.
11. Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine W, Zeh C, Agwale SM, Wambebe C, Odama L, Wiktor SZ. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004, 18:495-502. 10.1097/00002030-200402200-00016, 15090802.
12. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Pierard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008, 8:21. 10.1186/1471-2334-8-21, 2292191, 18304321.
13. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008, 22:665-666. 10.1097/QAD.0b013e3282f51203, 18317013.
14. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, Campa P, Chene G, Brun-Vezinet F, Descamps D. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008, 62:914-920. 10.1093/jac/dkn335, 18718922.
15. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009, 11:17-29.
16. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009, 83:10245-10249. 10.1128/JVI.00894-09, 2747997, 19605484.
17. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008, 22:1091-1092. 10.1097/QAD.0b013e3282f9b165, 18520356.
18. Salgado M, Toro C, Simon A, Garrido C, Blanco F, Soriano V, Rodes B. Mutation N155 H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009, 46:173-175. 10.1016/j.jcv.2009.06.020, 19625211.
19. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, Cook P, Workman J, Graham S, Smit E. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses 2009, 25:843-847. 10.1089/aid.2009.0039, 19618998.
20. Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 1997, 4:567-577. 10.1038/nsb0797-567, 9228950.
21. Eijkelenboom AP, Sprangers R, Hard K, Puras Lutzke RA, Plasterk RH, Boelens R, Kaptein R. Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. Proteins 1999, 36:556-564. 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6, 10450096.
22. Eijkelenboom AP, van den Ent FM, Wechselberger R, Plasterk RH, Kaptein R, Boelens R. Refined solution structure of the dimeric N-terminal HHCC domain of HIV-2 integrase. J Biomol NMR 2000, 18:119-128. 10.1023/A:1008342312269, 11101216.
23. Dar MJ, Monel B, Krishnan L, Shun MC, Di Nunzio F, Helland DE, Engelman A. Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology 2009, 6:94. 10.1186/1742-4690-6-94, 2770994, 19840380.
24. Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, Artese A, Costa G, Bono S, Alcaro S, Monforte A, Katlama C, Calvez V, Antinori A, Marcelin AG, Perno CF. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010, 65:2305-2318. 10.1093/jac/dkq326, 20817922.
25. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004, 4:965-977. 10.2174/1568026043388547, 15134551.
26. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007, 12:563-570.
27. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA 1996, 93:13659-13664. 10.1073/pnas.93.24.13659, 19383, 8942990.
28. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001, 20:7333-7343. 10.1093/emboj/20.24.7333, 125787, 11743009.
29. Wang T, Piefer AJ, Jonsson CB. Interactions of the human T-cell leukemia virus type-II integrase with the conserved CA in the retroviral long terminal repeat end. J Biol Chem 2001, 276:14710-14717. 10.1074/jbc.M007754200, 11278363.
30. Padow M, Lai L, Deivanayagam C, DeLucas LJ, Weiss RB, Dunn DM, Wu X, Kappes JC. Replication of chimeric human immunodeficiency virus type 1 (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis. J Virol 2003, 77:11050-11059. 10.1128/JVI.77.20.11050-11059.2003, 224969, 14512553.
31. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74. 10.1186/1742-4690-5-74, 2546438, 18687142.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
33. Savarino A. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007, 4:21. 10.1186/1742-4690-4-21, 1847836, 17374162.
34. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, Moreau J, Tamalet C. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004, 42:570-577. 10.1128/JCM.42.2.570-577.2004, 344439, 14766818.
35. Miyoshi I, Taguchi H, Fujishita M, Niiya K, Kitagawa T, Ohtsuki Y, Akagi T. Asymptomatic type C virus carriers in the family of an adult T-cell leukemia patient. Gann 1982, 73:339-340.
36. Harada S, Koyanagi Y, Yamamoto N. Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events. Virology 1985, 146:272-281. 10.1016/0042-6822(85)90010-8, 2413616.
37. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985, 229:563-566. 10.1126/science.2992081, 2992081.
38. Ruelle J, Mukadi BK, Schutten M, Goubau P. Quantitative real-time PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2). J Virol Methods 2004, 117:67-74. 10.1016/j.jviromet.2003.12.006, 15019261.
39. Ruelle J, Sanou M, Liu HF, Vandenbroucke AT, Duquenne A, Goubau P. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses 2007, 23:955-964. 10.1089/aid.2007.0034, 17725411.
40. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988, 20:309-321. 10.1016/0166-0934(88)90134-6, 2460479.